Education
About Us
Working with TipRanks
Follow Us
Caplin Point Laboratories Limited (IN:CAPLIPOINT)
:CAPLIPOINT
CAPLIPOINT Stock Chart & Stats
₹1845.95
-₹76.70(-2.97%)
At close: 4:00 PM EST
₹1845.95
-₹76.70(-2.97%)
Day’s Range― - ―
52-Week Range₹1,551.05 - ₹2,396.95
Previous CloseN/A
Volume128.91K
Average Volume (3M)3.75K
Market Cap
₹127.32B
Enterprise Value₹119.08B
Total Cash (Recent Filing)₹9.03B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)21.3
Beta1.42
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.31%
Share Statistics
EPS (TTM)21.80
Shares Outstanding76,011,696
10 Day Avg. Volume2,866
30 Day Avg. Volume3,752
Financial Highlights & Ratios
PEG Ratio1.63
Price to Book (P/B)5.30
Price to Sales (P/S)7.78
P/FCF Ratio62.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)85.1
Revenue Forecast (FY)₹22.39B
Bulls Say, Bears Say
Bulls Say
Revenue Growth & MarginsConsistent multi-year revenue growth combined with robust gross, EBIT and EBITDA margins indicates durable product demand and operational efficiency. Strong margins suggest pricing power in differentiated products and capacity to reinvest in registrations, supporting sustainable cash generation and scalability.
Balance Sheet StrengthA low leverage profile and high equity ratio provide financial flexibility to fund regulatory approvals, capex for complex dosage forms, or weather tender volatility. Prudent leverage reduces refinancing risk and preserves capacity for strategic investments without pressuring cash flow.
Cash Flow GenerationSustained operating cash conversion and rising free cash flow underpin the company’s ability to self-fund manufacturing upgrades, expand registrations across regulated markets, and pay down debt. Reliable cash generation supports long-term competitiveness and capital allocation optionality.
Bears Say
Geographic & Regulatory ExposureHeavy reliance on multiple regulated and semi-regulated overseas markets creates persistent regulatory, inspection and market-access risks. Approval delays, differing standards and partner execution can slow launches and sustain revenue uncertainty across quarters and years.
Concentration In Complex Dosage FormsFocus on injectables and ophthalmics brings durable advantages but also structural risks: higher manufacturing complexity, stricter quality control and larger validation cycles. These raise capex and operational risk and can constrain capacity or cause prolonged disruptions if issues arise.
Tender-driven Revenue DependenceMaterial exposure to tender and contract bidding creates structural revenue lumpiness and pricing pressure. Reliance on winning competitive bids makes volumes volatile and margins sensitive to tender dynamics, limiting predictability of medium-term revenue and earnings.
Caplin Point Laboratories Limited News
CAPLIPOINT FAQ
What was Caplin Point Laboratories Limited’s price range in the past 12 months?
Caplin Point Laboratories Limited lowest stock price was ₹1551.05 and its highest was ₹2396.95 in the past 12 months.
What is Caplin Point Laboratories Limited’s market cap?
Caplin Point Laboratories Limited’s market cap is ₹127.32B.
When is Caplin Point Laboratories Limited’s upcoming earnings report date?
Caplin Point Laboratories Limited’s upcoming earnings report date is May 14, 2026 which is in 70 days.
How were Caplin Point Laboratories Limited’s earnings last quarter?
Caplin Point Laboratories Limited released its earnings results on Feb 05, 2026. The company reported ₹21.8 earnings per share for the quarter, beating the consensus estimate of N/A by ₹21.8.
Is Caplin Point Laboratories Limited overvalued?
According to Wall Street analysts Caplin Point Laboratories Limited’s price is currently Overvalued.
Does Caplin Point Laboratories Limited pay dividends?
Caplin Point Laboratories Limited pays a Quarterly dividend of ₹3 which represents an annual dividend yield of 0.31%. See more information on Caplin Point Laboratories Limited dividends here
What is Caplin Point Laboratories Limited’s EPS estimate?
Caplin Point Laboratories Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Caplin Point Laboratories Limited have?
Caplin Point Laboratories Limited has 76,011,696 shares outstanding.
What happened to Caplin Point Laboratories Limited’s price movement after its last earnings report?
Caplin Point Laboratories Limited reported an EPS of ₹21.8 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.419%.
Which hedge fund is a major shareholder of Caplin Point Laboratories Limited?
Currently, no hedge funds are holding shares in IN:CAPLIPOINT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Caplin Point Laboratories Limited
Caplin Point Laboratories Limited develops, produces, markets, and exports generic pharmaceutical formulations and branded products in India. The company provides liquid and lyophilized injections, ophthalmic products, tablets, liquid orals, capsules, softgel capsules, suppositories and ovules, powder for injection, dry syrups, topicals, inhalers, IV infusions, lyophilized products, branded products, dermo cosmetics, and other products. It also operates QueTenX, an e-commerce website. The company was incorporated in 1990 and is headquartered in Chennai, India.
Technical Analysis
Alembic Pharmaceuticals Limited
―
―
Granules India Limited
―
NATCO Pharma Limited
―
Neuland Laboratories Ltd.
―